Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Precision and Future Medicine · 31.12.2021 · 5 (4) · 151-163
DOI: 10.23838/pfm.2021.00128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Precision and Future Medicine, erschienen am 31.12.2021. Verfasst von Ji Young Chang und 1 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The development of treatment options has revolutionized the prognosis of inflammatory bowel disease (IBD). However, a particular group of patients still experience therapeutic failure or drug side effects. Although the high inter-patient variability in therapy is associated with clinical factors, including age, disease behavior, and disease duration, they attribute only a small proportion of inter-individual variability. Thus, pharmacogenetics evaluating associations between specific genetic variations and drug responses or side effects have focused on optimizing therapeutic efficacy and minimizing toxicity in IBD treatment. Thiopurine S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) are well-established predictive markers of thiopurine-induced myelosuppression. Low TPMT activity is related to increased 6-thioguanine nucleotide levels, subsequently leading to myelotoxicity. NUDT15 variants are strongly associated with thiopurine-induced early leukopenia in Asians, with a lower incidence of TPMT-deficient allele. The Korean Association for the Study of Intestinal Diseases guidelines recommend pretreatment determination of NUDT15 genotypes, especially in East Asians, and NUDT15 R139C measurement has been approved for clinical use since 2019. Several studies have attempted to identify powerful genetic markers for personalized medicine. In this article, we review the identified pharmacogenetics of currently available drugs, focusing on 5-aminosalicylic acid, glucocorticosteroids, thiopurines, and anti-tumor necrosis factor-alpha agents.
Zitieren
APA
Chang, J. Y., & Cheon, J. H. (2021). Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precision and Future Medicine, 5(4), 151-163. https://doi.org/10.23838/pfm.2021.00128
Vancouver
Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precision and Future Medicine. 2021;5(4):151-163. doi:10.23838/pfm.2021.00128
BibTeX
@article{Chang2021,
author = {Chang, Ji Young and Cheon, Jae Hee},
title = {Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review},
journal = {Precision and Future Medicine},
year = {2021},
volume = {5},
number = {4},
pages = {151--163},
doi = {10.23838/pfm.2021.00128}
}
EUVIMED